Medical Need´s partner company, announces positive data from study with MD 1003 for treatment of progressive MS


Paris, France, April 24 2015 - MedDay, a biotechnology company focused on the treatment of nervous system disorders, today announced positive results from the pivotal Phase III clinical trial, MS-SPI, which showed evidence of the efficacy and safety of MD1003, a highly-concentrated pharmaceutical-grade biotin administered at a dose of 300 mg per day in the treatment of primary and secondary progressive multiple sclerosis, a major area of unmet medical need.

The primary endpoint was met with a proportion of MS patients showing an improvement in EDSS or TW25 at Month 9 and confirmed at Month 12 (p = 0.0051). The primary endpoint was supported by evidence of a substantial decrease in the risk of disease progression.

The MS-SPI study was a randomized 2:1, double-blinded, placebo-controlled study conducted in 16 MS reference centres in France. Treatment duration was one year.

Read the full press release here.

Related news:

Medical Need exclusive supply and distribution agreement with French company MedDay Pharmaceuticals, relating to their product MD-1003 (December 12, 2013):

Medical Need gains rights to product for the treatment of progressive multiple sclerosis (MS)